Northern Trust Corp Tg Therapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,412,144 shares of TGTX stock, worth $43.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,412,144

Previous 1,276,317 10.64%

Holding current value

$43.6 Million

Previous $22.7 Million 45.47%

% of portfolio

0.01%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$17.21 - $25.28 $2.34 Million - $3.43 Million	135,827 Added 10.64%	1,412,144 $33 Million
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $320,625 - $461,922	-24,071 Reduced 1.85%	1,276,317 $22.7 Million
Q1 2024 May 14, 2024	SELL	$13.02 - $21.3 $658,121 - $1.08 Million	-50,547 Reduced 3.74%	1,300,388 $19.8 Million
Q4 2023 Feb 13, 2024	SELL	$6.68 - $18.81 $47,180 - $132,855	-7,063 Reduced 0.52%	1,350,935 $23.1 Million
Q3 2023 Nov 13, 2023	BUY	$8.36 - $26.5 $76,895 - $243,747	9,198 Added 0.68%	1,357,998 $11.4 Million
Q2 2023 Aug 11, 2023	BUY	$15.48 - $35.0 $728,070 - $1.65 Million	47,033 Added 3.61%	1,348,800 $33.5 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $316,812 - $598,940	30,969 Added 2.44%	1,301,767 $19.6 Million
Q4 2022 Feb 13, 2023	BUY	$5.01 - $11.83 $80,185 - $189,339	16,005 Added 1.28%	1,270,798 $15 Million
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $45,261 - $83,193	9,904 Added 0.8%	1,254,793 $7.43 Million
Q2 2022 Aug 12, 2022	SELL	$3.74 - $10.66 $29,284 - $83,467	-7,830 Reduced 0.63%	1,244,889 $5.29 Million
Q1 2022 May 13, 2022	SELL	$7.81 - $20.45 $437,758 - $1.15 Million	-56,051 Reduced 4.28%	1,252,719 $11.9 Million
Q4 2021 Feb 08, 2022	SELL	$15.2 - $35.51 $85,880 - $200,631	-5,650 Reduced 0.43%	1,308,770 $24.9 Million
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $1.08 Million - $2.01 Million	-49,777 Reduced 3.65%	1,314,420 $43.7 Million
Q2 2021 Aug 13, 2021	BUY	$32.5 - $48.96 $962,130 - $1.45 Million	29,604 Added 2.22%	1,364,197 $52.9 Million
Q1 2021 May 12, 2021	SELL	$41.61 - $54.3 $830,743 - $1.08 Million	-19,965 Reduced 1.47%	1,334,593 $64.3 Million
Q4 2020 Feb 11, 2021	BUY	$25.27 - $54.9 $237,007 - $514,907	9,379 Added 0.7%	1,354,558 $70.5 Million
Q3 2020 Nov 16, 2020	BUY	$18.49 - $27.24 $1.42 Million - $2.1 Million	76,923 Added 6.07%	1,345,179 $36 Million
Q2 2020 Aug 14, 2020	BUY	$8.9 - $21.84 $1.37 Million - $3.37 Million	154,157 Added 13.84%	1,268,256 $24.7 Million
Q1 2020 May 14, 2020	BUY	$7.14 - $15.99 $205,589 - $460,416	28,794 Added 2.65%	1,114,099 $11 Million
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $128,494 - $282,184	25,195 Added 2.38%	1,085,305 $12 Million
Q3 2019 Nov 13, 2019	BUY	$5.38 - $8.99 $1.17 Million - $1.95 Million	216,967 Added 25.73%	1,060,110 $5.95 Million
Q2 2019 Aug 13, 2019	BUY	$6.27 - $8.65 $208,164 - $287,180	33,200 Added 4.1%	843,143 $7.29 Million
Q1 2019 May 13, 2019	BUY	$4.02 - $8.04 $33,699 - $67,399	8,383 Added 1.05%	809,943 $6.51 Million
Q4 2018 Feb 12, 2019	SELL	$3.44 - $5.76 $71,823 - $120,263	-20,879 Reduced 2.54%	801,560 $3.29 Million
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $364,177 - $989,996	70,714 Added 9.41%	822,439 $4.61 Million
Q2 2018 Sep 18, 2018	SELL	$12.5 - $15.0 $50,075 - $60,090	-4,006 Reduced 0.53%	751,725 $9.89 Million
Q2 2018 Aug 14, 2018	BUY	$12.5 - $15.0 $1.57 Million - $1.88 Million	125,430 Added 19.9%	755,731 $9.94 Million
Q1 2018 May 09, 2018	BUY	$8.7 - $16.8 $108,897 - $210,285	12,517 Added 2.03%	630,301 $8.95 Million
Q4 2017 Feb 14, 2018	BUY	$7.35 - $12.3 $153,512 - $256,897	20,886 Added 3.5%	617,784 $5.07 Million
Q3 2017 Nov 13, 2017	BUY	$10.0 - $12.7 $5.97 Million - $7.58 Million	596,898	596,898 $7.07 Million

Others Institutions Holding TGTX

# of Institutions

335

Shares Held

88.3M

Call Options Held

2.08M

Put Options Held

1.51M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.48B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Tg Therapeutics, Inc. Transaction History